Volume 11, Issue 3 ( September 2019 2019)
Iranian Journal of Blood and Cancer 2019, 11(3): 96-100 |
Back to browse issues page
Sanjana Zaman1 
, Hiroko Fukushima2 , Ryoko Suzuki3 , Shoji Yoshimatsu4 , Mohammad Delwer Hossain Hawlader * 5, Takashi Fukushima2
, Hiroko Fukushima2 , Ryoko Suzuki3 , Shoji Yoshimatsu4 , Mohammad Delwer Hossain Hawlader * 5, Takashi Fukushima2
1- North South University
2- University of Tsukuba
3- Department of Child Health, Graduate School of Comprehensive Human Sciences Majors of Medical Sciences, University of Tsukuba
4- Research Institute of Tuberculosis, Tokyo
5- North South University , mohammad.hawlader@northsouth.edu
2- University of Tsukuba
3- Department of Child Health, Graduate School of Comprehensive Human Sciences Majors of Medical Sciences, University of Tsukuba
4- Research Institute of Tuberculosis, Tokyo
5- North South University , mohammad.hawlader@northsouth.edu
Abstract: (4821 Views)
Background: The pharmacogenetic-oriented approach reduces the toxicity and increases the safety of chemotherapeutic agents. 6-mercaptopurin (6-MP) metabolizing enzymes such as thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) contribute to variable responses and adverse effects among leukemia patients treated with 6-MP. The aim of our study was to identify the prevalence of TPMT and ITPA gene polymorphisms among Bangladeshi children with acute lymphoblastic leukemia (ALL) and their association with the adverse effects of 6-MP during the treatment.
Methods: We recruited 75 patients with ALL and 75 volunteers with minor illnesses as the control group. Genotyping for TPMT (TPMT*3C, *3B, *2) and ITPA (ITPAc.94C>.A) was performed. The relationship between genotypes and adverse effects of 6-MP was investigated.
Results: The frequency of TPMT*3B, TPMT*3C and ITPA polymorphisms among volunteers was 0.006, 0.020, and 0.093, respectively, whereas TPMT*3C and ITPA polymorphisms among ALL patients was 0.010 and 0.153, respectively. ALL patients with the ITPA variant developed fever (OR=6.9, 95% CI=1.99-23.91), neutropenia (OR=7.68, 95% CI=2.21-26.61), hyperbilirubinemia (OR=4.73, 95% CI=1.39-16.07) and raised serum ALT (OR=4.73, 95% CI=1.52-14.68) which were significant in comparison with those without polymorphism.
Conclusion: The frequency of ITPAc.94C>A among Bangladeshi children was high. Adverse effects of chemotherapy in patients with ALL suggests the importance of ITPA genotyping in ALL patients prior to starting chemotherapy.
Methods: We recruited 75 patients with ALL and 75 volunteers with minor illnesses as the control group. Genotyping for TPMT (TPMT*3C, *3B, *2) and ITPA (ITPAc.94C>.A) was performed. The relationship between genotypes and adverse effects of 6-MP was investigated.
Results: The frequency of TPMT*3B, TPMT*3C and ITPA polymorphisms among volunteers was 0.006, 0.020, and 0.093, respectively, whereas TPMT*3C and ITPA polymorphisms among ALL patients was 0.010 and 0.153, respectively. ALL patients with the ITPA variant developed fever (OR=6.9, 95% CI=1.99-23.91), neutropenia (OR=7.68, 95% CI=2.21-26.61), hyperbilirubinemia (OR=4.73, 95% CI=1.39-16.07) and raised serum ALT (OR=4.73, 95% CI=1.52-14.68) which were significant in comparison with those without polymorphism.
Conclusion: The frequency of ITPAc.94C>A among Bangladeshi children was high. Adverse effects of chemotherapy in patients with ALL suggests the importance of ITPA genotyping in ALL patients prior to starting chemotherapy.
Keywords: TPMT gene polymorphisms, ITPA enzyme, Polymorphism, Acute lymphoblastic leukemia, Children, 6-mercaptopurine toxicity
: Original Article |
Subject:
Pediatric Hematology & Oncology
Received: 2019/03/3 | Accepted: 2019/08/29 | Published: 2019/10/8
Received: 2019/03/3 | Accepted: 2019/08/29 | Published: 2019/10/8
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |